financetom
Business
financetom
/
Business
/
Cintas' Fiscal Q3 Beat Showcases Sustained Organic Growth, Margin Expansion, Oppenheimer Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cintas' Fiscal Q3 Beat Showcases Sustained Organic Growth, Margin Expansion, Oppenheimer Says
Mar 26, 2026 12:39 PM

03:00 PM EDT, 03/26/2026 (MT Newswires) -- Cintas' ( CTAS ) fiscal Q3 beat underlines sustained organic growth, margin expansion, and operational execution, Oppenheimer said in a Wednesday research note.

The brokerage said it now expects adjusted EPS for 2026 and 2027 of $4.88 and $5.37, respectively, from $4.84 and $5.33 earlier.

The company's multi-year contracts, robust balance sheet, and stable cash flow are favorable attributes, according to the note.

The brokerage has a perform rating on the stock.

Price: 170.15, Change: -6.70, Percent Change: -3.79

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
High Tide, Aurora Cannabis Mixed In US Premarket Trade As Both Note Start of German Cannabis Legalization
High Tide, Aurora Cannabis Mixed In US Premarket Trade As Both Note Start of German Cannabis Legalization
Apr 1, 2024
08:45 AM EDT, 04/01/2024 (MT Newswires) -- Both High Tide Inc. ( HITI ) and Aurora Cannabis Inc. ( ACB ) on Monday applauded the start of cannabis legalization in Germany following the German government's final endorsement. German adults will now be allowed to possess up to 25 grams of cannabis and grow up to three plants for personal use,...
AstraZeneca's Hemolysis Drug Approved by FDA; Advisors Urge Shareholders to Nix CEO Pay Raise
AstraZeneca's Hemolysis Drug Approved by FDA; Advisors Urge Shareholders to Nix CEO Pay Raise
Apr 1, 2024
08:48 AM EDT, 04/01/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Monday that its drug Voydeya has been approved by the US Food and Drug Administration as add-on therapy to ravulizumab or eculizumab to treat extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria. The FDA approval of the drug followed results from a 12-week study that met its primary...
Browning West's Director Candidates Releases Five-Pillar Plan to Boost Shareholder Value at Gildan Activewear; Former Gildan CEO Interview With Bloomberg News
Browning West's Director Candidates Releases Five-Pillar Plan to Boost Shareholder Value at Gildan Activewear; Former Gildan CEO Interview With Bloomberg News
Apr 1, 2024
08:47 AM EDT, 04/01/2024 (MT Newswires) -- Browning West, LP, a long-term shareholder of Gildan Activewear Inc. ( GIL ) that owns 5.0% of its outstanding shares, on Monday said its slate of director candidates has released a presentation detailing its five-pillar plan to increase Gildan's share price to more than US$60 by the end of 2025 and more than...
Liberty Media Strikes 4.2 Billion-Euro Deal to Buy MotoGP Commercial Rights Holder
Liberty Media Strikes 4.2 Billion-Euro Deal to Buy MotoGP Commercial Rights Holder
Apr 1, 2024
08:48 AM EDT, 04/01/2024 (MT Newswires) -- Liberty Media ( LLYVB ) (FWONA, FWONK) on Monday agreed to acquire Dorna Sports, the exclusive commercial rights holder to the MotoGP World Championship, in a deal with an enterprise value of about 4.2 billion euros ($4.53 billion). The mass media company, which has ownership stakes in Formula One and Sirius XM (SIRI),...
Copyright 2023-2026 - www.financetom.com All Rights Reserved